{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-024956","form_type":"8-K","ticker":"DMAC","cik":"0001401040","company_name":"DiaMedica Therapeutics Inc.","filed_at":"2025-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.894412+00:00","generated_at":"2026-05-17T19:02:33.791700+00:00","sec_items":["5.02","7.01","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"DiaMedica CMO Lorianne Masuoka resigns; Julie Krop appointed as successor","bullets":["Lorianne Masuoka resigned as CMO effective Aug 4, 2025 for personal reasons; separation agreement provides health benefits through Oct 2026.","Julie Krop appointed as CMO effective Aug 11, 2025; Krop brings 20+ years experience, most recently CMO at PureTech Health.","Krop previously CMO at Freeline Therapeutics and AMAG Pharmaceuticals; involved in preeclampsia drug development at AMAG.","Krop will lead clinical development of DM199 for preeclampsia and acute ischemic stroke."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-024956","json":"https://secwatch.observer/filing/0001437749-25-024956.json","markdown":"https://secwatch.observer/filing/0001437749-25-024956.md","text":"https://secwatch.observer/filing/0001437749-25-024956.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1401040/000143774925024956/0001437749-25-024956-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1401040/000143774925024956/dmtp20250805_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T19:02:33.791700+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}